The high rate of both response [21] and resistance development [10] of BRAF-mutant melanoma patients to BRAF inhibitor (BRAFi) treatment has made such cell lines important models for understanding challenges associated with targeted inhibitors [9, 10]. The gene discussed is BRAF; the disease is melanoma.